U.S. markets open in 8 hours 31 minutes

Check-Cap Ltd. (CHEK)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.7300+0.0250 (+1.47%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Continuation Wedge (Bearish)

Continuation Wedge (Bearish)

Previous Close1.7050
Open1.7000
Bid0.0000 x 3200
Ask0.0000 x 2900
Day's Range1.6750 - 1.7500
52 Week Range0.2430 - 4.4900
Volume1,454,959
Avg. Volume14,708,031
Market Cap121.876M
Beta (5Y Monthly)0.28
PE Ratio (TTM)N/A
EPS (TTM)-0.4560
Earnings DateMar 19, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Check-Cap Reports Fourth Quarter and Full Year 2020 Financial Results
    PR Newswire

    Check-Cap Reports Fourth Quarter and Full Year 2020 Financial Results

    Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free, screening test to detect polyps before they may transform into colorectal cancer (CRC), today announced financial results for the fourth quarter and full year ended December 31, 2020.

  • Check-Cap Receives FDA IDE Approval for Pivotal Study of C-Scan®
    PR Newswire

    Check-Cap Receives FDA IDE Approval for Pivotal Study of C-Scan®

    Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan® , the first and only patient-friendly, preparation-free, screening test to detect polyps before they may transform into colorectal cancer (CRC), today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Investigational Device Exemption (IDE) application, permitting Check-Cap to begin a pivotal study of C-Scan in the U.S. C-Scan is intended for candidates who are at average-risk for CRC and who are poor candidates for colonoscopy or decline colonoscopy, or who had an incomplete optical colonoscopy. The pivotal study will evaluate safety and performance of C-Scan as well as subject compliance with C-Scan.

  • TheStreet.com

    Check-Cap Doubles; FDA OKs Request to Study Polyp-Detection Test

    Check-Cap stock jumped after the FDA cleared the company to conduct a study of a test to detect polyps that could become colorectal cancer.